---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-13T19:35:31.970187'
end_time: '2026-01-13T19:41:58.123474'
duration_seconds: 386.15
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: NOVA2
  gene_symbol: NOVA2
  uniprot_accession: Q9UNW9
  protein_description: 'RecName: Full=RNA-binding protein Nova-2 {ECO:0000305}; AltName:
    Full=Astrocytic NOVA1-like RNA-binding protein; AltName: Full=Neuro-oncological
    ventral antigen 2;'
  gene_info: Name=NOVA2 {ECO:0000312|HGNC:HGNC:7887}; Synonyms=ANOVA, NOVA3;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: KH-I_NOVA_rpt1. (IPR047275); KH-I_NOVA_rpt2. (IPR047276); KH-I_NOVA_rpt3.
    (IPR047274); KH_dom. (IPR004087); KH_dom_type_1. (IPR004088)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 10
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9UNW9
- **Protein Description:** RecName: Full=RNA-binding protein Nova-2 {ECO:0000305}; AltName: Full=Astrocytic NOVA1-like RNA-binding protein; AltName: Full=Neuro-oncological ventral antigen 2;
- **Gene Information:** Name=NOVA2 {ECO:0000312|HGNC:HGNC:7887}; Synonyms=ANOVA, NOVA3;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** KH-I_NOVA_rpt1. (IPR047275); KH-I_NOVA_rpt2. (IPR047276); KH-I_NOVA_rpt3. (IPR047274); KH_dom. (IPR004087); KH_dom_type_1. (IPR004088)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "NOVA2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'NOVA2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **NOVA2** (gene ID: NOVA2, UniProt: Q9UNW9) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9UNW9
- **Protein Description:** RecName: Full=RNA-binding protein Nova-2 {ECO:0000305}; AltName: Full=Astrocytic NOVA1-like RNA-binding protein; AltName: Full=Neuro-oncological ventral antigen 2;
- **Gene Information:** Name=NOVA2 {ECO:0000312|HGNC:HGNC:7887}; Synonyms=ANOVA, NOVA3;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** KH-I_NOVA_rpt1. (IPR047275); KH-I_NOVA_rpt2. (IPR047276); KH-I_NOVA_rpt3. (IPR047274); KH_dom. (IPR004087); KH_dom_type_1. (IPR004088)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "NOVA2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'NOVA2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **NOVA2** (gene ID: NOVA2, UniProt: Q9UNW9) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive research report: NOVA2 (UniProt Q9UNW9)

Gene/protein verification and identity
- Symbol and organism: NOVA2 encodes the human RNA-binding protein Nova-2, a member of the neuronal NOVA family originally identified as a paraneoplastic autoantigen and subsequently recognized as a key splicing regulator in neurons and endothelium (position-dependent alternative splicing regulator). This matches the provided identity and organism (Homo sapiens). NOVA proteins are characterized by KH-type RNA-binding domains that recognize YCAY motifs in RNA, in line with the UniProt domain annotations for KH repeats (KH-I_NOVA repeat modules and type-1 KH domains) (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4, kremer2023neurooncologicalventralantigen pages 1-2).

Key concepts and definitions
- Molecular function: NOVA2 is an RNA-binding splicing regulator that recognizes YCAY motif clusters (Y = C/U) within pre-mRNAs to control alternative splicing; it also has roles in 3′UTR binding and alternative polyadenylation for select targets (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4, kremer2023neurooncologicalventralantigen pages 1-2).
- RNA motif specificity: YCAY clusters are the canonical recognition elements; functional and CLIP-driven studies consistently identify these sequence motifs near regulated exons and polyadenylation elements (moakley2024oncogenicnova1expression pages 4-7, yang2023nova1preventsoveractivation pages 9-10, kremer2023neurooncologicalventralantigen pages 1-2).
- Position-dependent “RNA map” logic: Binding upstream (5′ intron) of an alternative exon typically promotes exon skipping; binding downstream (3′ intron) promotes exon inclusion. Binding near/within 3′UTRs can modulate alternative polyadenylation site usage. This logic has been reproduced across systems (neuronal and cancer) and is foundational to NOVA2 regulation (moakley2024oncogenicnova1expression pages 4-7, kremer2023neurooncologicalventralantigen pages 1-2).
- Cellular/subcellular localization: NOVA proteins act in the nucleus to regulate co-transcriptional splicing. Evidence also supports binding to 3′UTRs and localization with target mRNAs in neuronal compartments, indicating functions that can extend to cytoplasmic RNA regulation for specific transcripts (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4).

Recent developments and latest research (emphasis 2023–2024)
- Endothelial splicing and angiogenesis: In human umbilical vein endothelial cells (HUVECs), NOVA2 directly binds FLT1 mRNA and represses production of soluble FLT1 (sFLT1) splice variants; NOVA2 knockdown increases sFLT1 without changing membrane FLT1, impairs endothelial sprouting, and sprouting is rescued by exogenous VEGF, implicating VEGF sequestration by sFLT1. A negative correlation between NOVA2 and sFLT1 was observed in placental samples, highlighting a clinically relevant regulatory axis. These findings consolidate NOVA2’s role in vascular/endothelial function beyond the nervous system (Aug 2023; URL: https://doi.org/10.1007/s43032-022-01044-4) (kremer2023neurooncologicalventralantigen pages 1-2).
- Neuronal programs and target scope: A 2024 review synthesizes NOVA1/2’s neuronal splicing networks, summarizing HITS-CLIP and knockout analyses that identified on the order of approximately 700 NOVA targets in brain, with about 15% of targets exhibiting co-regulation with RBFOX family proteins. Many targets encode synaptic/phosphoproteins, including microexon-containing events that alter protein–protein interaction potential. The review also emphasizes region- and neuronal subtype-specific roles for NOVA2, such as in cortical lamination via Dab1 splicing and divergent regulation of shared targets across neuron classes (Dec 2024; URL: https://doi.org/10.4103/1673-5374.390976) (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4).
- Position-dependent rules reproduced in human cancer: Although focused on NOVA1, a 2024 analysis of breast tumors shows ectopic NOVA expression reinstates the canonical NOVA RNA map, with neuron-like exon choices and widespread differential splicing events (e.g., 226 and 158 DSEs in Luminal A/B with |ΔPSI|≥0.2, FDR<0.05), supporting the generality of NOVA position-dependent regulation and its potential impact outside the brain (Jul 2024 preprint; URL: https://doi.org/10.1101/2024.07.08.602566) (moakley2024oncogenicnova1expression pages 4-7).
- Methodological advances informing NOVA2 biology: High-quality CLIP-seq integration with RNA-seq in human adipogenesis (NOVA1 case study) demonstrated strong replicate concordance (Spearman R > 0.93), motif/position analyses, and causal validation with minigenes (e.g., NCOR2 exon 47). While centered on NOVA1, the approach and motif logic apply broadly to NOVA2 target discovery and validation (May 2023; URL: https://doi.org/10.1093/nar/gkad469) (yang2023nova1preventsoveractivation pages 9-10).

Current applications and real-world implementations
- Endothelial dysfunction models and biomarkers: NOVA2’s regulation of FLT1/sFLT1 suggests utility in endothelial function assays and disease models where sFLT1 is pathogenic, such as preeclampsia. The placental negative correlation between NOVA2 and sFLT1 supports exploration of NOVA2-linked readouts as biomarkers or mechanistic endpoints in vascular disorders (kremer2023neurooncologicalventralantigen pages 1-2).
- Cancer transcriptome state and prognosis: Ectopic NOVA-driven splicing programs in breast cancer demonstrate that NOVA activity can rewire cell-periphery and cytoskeleton gene networks; associations with subtype and prognosis in the study argue for considering NOVA activity as a feature of tumor stratification and potentially as a functional biomarker of RNA-processing states. Although this analysis focused on NOVA1, the RNA map logic and YCAY motif dependence are conserved with NOVA2 (moakley2024oncogenicnova1expression pages 4-7).
- Systems-level neurobiology: The neuronal review implicates NOVA2 in programs shaping cortical development and synaptic gene isoforms; such programs provide testable axes for circuit-level phenotyping and for selecting splicing events as pharmacodynamic readouts in neurodevelopmental models (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4).

Expert opinions and authoritative analyses
- Post-transcriptional neurogenesis framework: The 2024 Neural Regeneration Research review emphasizes NOVA1/2 as central splicing regulators in neuronal development, highlights the scale of their target networks, and underscores combinatorial control with RBFOX, providing a consensus view of NOVA2’s importance and mechanistic logic in the nervous system (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4).
- Endothelial functional importance: The 2023 endothelial study concludes NOVA2 is required for endothelial function and directly modulates FLT1 splicing, consolidating its role in angiogenesis-related pathways and endorsing NOVA2 as a regulator with physiological and potential pathological significance in vasculature (kremer2023neurooncologicalventralantigen pages 1-2).

Relevant statistics and quantitative data
- Target scope: Approximately 700 NOVA targets identified in brain through combined HITS-CLIP and loss-of-function analyses; about 15% co-regulated with RBFOX factors, pointing to network-level integration (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4).
- Cancer splicing impact (NOVA RNA map generality): 226 and 158 differential splicing events (|ΔPSI|≥0.2, FDR<0.05) associated with high NOVA levels in Luminal A and B breast tumors, respectively, with 21 high-confidence events concordant with neuronal directionality; these data reinforce quantitative impact of NOVA activity in human tissues (moakley2024oncogenicnova1expression pages 4-7).
- CLIP methodological quality and integration: Replicate CLIP-seq correlation Spearman R > 0.93 in a NOVA study; integrated CLIP+RNA-seq implicated 46 genes with both binding and expression/splicing changes in one focused system, illustrating rigorous pipelines relevant to NOVA2 projects (yang2023nova1preventsoveractivation pages 9-10).
- Endothelial functional phenotypes: NOVA2 knockdown increases sFLT1, impairs sprouting, and sprouting is rescued by VEGF in HUVECs; placental NOVA2 and sFLT1 show a negative correlation—findings that provide mechanistic and correlative metrics in human-relevant material (kremer2023neurooncologicalventralantigen pages 1-2).

Biological processes, localization, and pathways
- Splicing regulatory pathways: NOVA2 executes a position-dependent splicing program using KH domains to bind YCAY motifs; downstream effects are enriched in synaptic/neuronal pathways in brain and in endothelial function/angiogenesis pathways in the vasculature (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4, kremer2023neurooncologicalventralantigen pages 1-2).
- Subcellular site of action: Predominantly nuclear splicing regulation, with evidence of 3′UTR interactions and presence with target mRNAs in neuronal compartments suggesting additional post-transcriptional roles for select transcripts (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4).
- Endothelial/angiogenic pathway integration: By regulating FLT1 splicing and thereby the balance of membrane FLT1 versus sFLT1, NOVA2 impacts VEGF availability and VEGF-driven signaling and morphogenetic behaviors such as sprouting (kremer2023neurooncologicalventralantigen pages 1-2).

Identity/domain verification summary
- The human NOVA2 protein contains three KH-type RNA-binding domains and binds YCAY motifs to regulate alternative splicing in a position-dependent manner; these features concur with the UniProt-provided KH domain annotations and NOVA family characteristics described in the literature (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4, kremer2023neurooncologicalventralantigen pages 1-2).

Key 2023–2024 sources table
| Year | Citation (First author et al., journal) | Focus / Key finding | Relevance to NOVA2 | URL |
|---|---|---|---|---|
| 2023 | Kremer et al., Reproductive Sciences (kremer2023neurooncologicalventralantigen pages 1-2) | NOVA2 regulates splicing of VEGFR1 (FLT1); NOVA2 loss increases soluble FLT1 (sFLT1) and impairs endothelial sprouting / function | Direct experimental evidence linking NOVA2 to endothelial alternative splicing and angiogenesis | https://doi.org/10.1007/s43032-022-01044-4 |
| 2024 | Papadimitriou & Thomaidou, Neural Regeneration Research (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4) | Review of post-transcriptional control in neurogenesis; summarizes NOVA1/2 neuronal splicing programs, position-dependent RNA map, and target counts from CLIP/KO studies (~700 targets noted) | Authoritative synthesis of NOVA family roles in neuronal alternative splicing, regulatory logic, and subcellular localization applicable to NOVA2 | https://doi.org/10.4103/1673-5374.390976 |
| 2024 | Moakley & Zhang, bioRxiv (moakley2024oncogenicnova1expression pages 4-7) | Ectopic NOVA1 in breast cancer activates neuron-like splicing programs; reports quantitative differential splicing events (e.g., 226 and 158 DSEs in subtypes) and reinforces position-dependent inclusion/skipping rules | Reinforces the NOVA RNA map and provides quantitative examples of splicing impacts relevant for interpreting NOVA2 effects in non-neuronal contexts | https://doi.org/10.1101/2024.07.08.602566 |
| 2023 | Yang et al., Nucleic Acids Research (yang2023nova1preventsoveractivation pages 9-10) | High-quality NOVA1 CLIP-seq during human adipogenesis (replicate Spearman R > 0.93); motif/position analysis and integrated CLIP+RNA-seq linking binding to functional splicing changes (e.g., NCOR2 exon 47) | Methodological and motif/position evidence (KH domain / YCAY logic) shared across NOVA proteins, supporting CLIP integration and functional validation approaches for NOVA2 | https://doi.org/10.1093/nar/gkad469 |


*Table: Compact summary of key 2023–2024 sources (experimental and review) relevant to human NOVA2, showing main findings, relevance to NOVA2 biology, and direct URLs for follow-up. Useful as a quick citation-ready reference for NOVA2 functional and methodological evidence. (kremer2023neurooncologicalventralantigen pages 1-2, papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4, moakley2024oncogenicnova1expression pages 4-7, yang2023nova1preventsoveractivation pages 9-10)*

Limitations
- Some highly topical 2024–2025 preprints and recent mechanistic studies (e.g., condensate-based cooperation at MAPT exon 10; evolutionary conservation of Agrin splicing) were not available in the curated evidence set here and thus are not cited; the report focuses on 2023–2024 peer-reviewed and select preprint sources with directly retrieved evidence (kremer2023neurooncologicalventralantigen pages 1-2, papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4, moakley2024oncogenicnova1expression pages 4-7, yang2023nova1preventsoveractivation pages 9-10).

URLs and dates (where available)
- Kremer et al., Reproductive Sciences, Aug 2023: https://doi.org/10.1007/s43032-022-01044-4 (kremer2023neurooncologicalventralantigen pages 1-2).
- Papadimitriou & Thomaidou, Neural Regeneration Research, Dec 2024: https://doi.org/10.4103/1673-5374.390976 (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4).
- Moakley & Zhang, bioRxiv, Jul 2024: https://doi.org/10.1101/2024.07.08.602566 (moakley2024oncogenicnova1expression pages 4-7).
- Yang et al., Nucleic Acids Research, May 2023: https://doi.org/10.1093/nar/gkad469 (yang2023nova1preventsoveractivation pages 9-10).

References

1. (papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4): Elsa Papadimitriou and Dimitra Thomaidou. Post-transcriptional mechanisms controlling neurogenesis and direct neuronal reprogramming. Neural Regeneration Research, 19:1929-1939, Dec 2024. URL: https://doi.org/10.4103/1673-5374.390976, doi:10.4103/1673-5374.390976. This article has 11 citations and is from a peer-reviewed journal.

2. (kremer2023neurooncologicalventralantigen pages 1-2): Veerle Kremer, Jetta J. Oppelaar, Theresa Gimbel, Susanne Koziarek, Wessel Ganzevoort, Mariëlle G. van Pampus, Bert-Jan van den Born, Liffert Vogt, Christianne de Groot, and Reinier A. Boon. Neuro-oncological ventral antigen 2 regulates splicing of vascular endothelial growth factor receptor 1 and is required for endothelial function. Reproductive Sciences, 30:678-689, Aug 2023. URL: https://doi.org/10.1007/s43032-022-01044-4, doi:10.1007/s43032-022-01044-4. This article has 3 citations and is from a peer-reviewed journal.

3. (moakley2024oncogenicnova1expression pages 4-7): Daniel F. Moakley and Chaolin Zhang. Oncogenic nova1 expression dysregulates alternative splicing in breast cancer. bioRxiv, Jul 2024. URL: https://doi.org/10.1101/2024.07.08.602566, doi:10.1101/2024.07.08.602566. This article has 1 citations and is from a poor quality or predatory journal.

4. (yang2023nova1preventsoveractivation pages 9-10): Zhigang Yang, Ping Dong, Jiankun Cao, Na Lin, Shize Ma, Rui Cao, L. Cai, Lei Wang, Changchang Cao, Yuanchao Xue, Jing Pan, Xiu-Bin Li, Kang Wang, Qiwei Liu, Chen Li, Fuxing Gong, Xinhui Fu, and Ran Xiao. Nova1 prevents overactivation of the unfolded protein response and facilitates chromatin access during human white adipogenesis. Nucleic Acids Research, 51:6981-6998, May 2023. URL: https://doi.org/10.1093/nar/gkad469, doi:10.1093/nar/gkad469. This article has 7 citations and is from a highest quality peer-reviewed journal.

## Citations

1. papadimitriou2024posttranscriptionalmechanismscontrolling pages 3-4
2. kremer2023neurooncologicalventralantigen pages 1-2
3. https://doi.org/10.1007/s43032-022-01044-4
4. https://doi.org/10.4103/1673-5374.390976
5. https://doi.org/10.1101/2024.07.08.602566
6. https://doi.org/10.1093/nar/gkad469
7. https://doi.org/10.4103/1673-5374.390976,
8. https://doi.org/10.1007/s43032-022-01044-4,
9. https://doi.org/10.1101/2024.07.08.602566,
10. https://doi.org/10.1093/nar/gkad469,